



## **ABIVAX to present at the Biotech Showcase™ during the JP Morgan Healthcare Conference San Francisco, January 11--13, 2016**

**Paris, France, December 17<sup>th</sup>, 2015** – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will present at the Biotech Showcase™ Annual Conference, to be held in San Francisco on January 11-- 13, 2016.

The Biotech Showcase™ conference is one of the largest annual international healthcare conferences and will run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11--14, 2016). Investors and biopharmaceutical executives from around the world gather in San Francisco during the second week of January at a series of events which are widely viewed as setting the tone for the coming year.

Professor Ehrlich's presentation at the Biotech Showcase™ is scheduled as follows:

Date: Tuesday, January 12, 2016  
Time: 10:30 AM  
Track: C -- Mission II (4th Floor)  
Venue: Parc 55 San Francisco - Union Square  
55 Cyril Magnin Street, San Francisco

**Biotech Showcase™** (#BTS2016) is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its 8<sup>th</sup> year, Biotech Showcase is expected to attract upwards of 2,000 attendees.

**ABIVAX** ([www.abivax.com](http://www.abivax.com)) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. Follow us on Twitter @ABIVAX\_

### **Contacts**

#### **Investor relations**

Raquel Lizarraga  
[raquel.lizarraga@abivax.com](mailto:raquel.lizarraga@abivax.com)  
m  
+33 1 53 83 09  
63

#### **Press relations**

**ALIZE RP**  
Caroline Carmagnol and Florence  
Portejoie

[abivax@alizerp.com](mailto:abivax@alizerp.com)  
+33 6 64 18 99 59 / + 33 1 44 54  
36 64

#### **Citigate Dewe Rogerson**

Lucie Languier  
[abivax@citigate.fr](mailto:abivax@citigate.fr)

#### **LifeSci Advisors**

Chris Maggos  
[chris@lifesciadvisors](mailto:chris@lifesciadvisors)

+33 1 53 32 84  
75

+41 79 367 6254

1